Peppermint Water BP 1973 THR 20346/0003 UKPAR
mhra par; peppermint water bp 1973, thr 20346/0003 3 peppermint water bp 1973 thr 20346/0003 scientific discussion table of contents introduction
Tags:
Scientific, Discussion, Peppermint, Scientific discussion
Information
Domain:
Source:
Link to this page:
Please notify us if you found a problem with this document:
Documents from same domain
Cefixime 400 mg Film-coated Tablets, PL 22805 …
www.mhra.gov.ukMHRA PAR; CEFIXIME 400 MG FILM-COATED TABLETS, PL 22805/0032-3 2 Lay summary The Medicines and Healthcare products Regulatory Agency …
Meloxicam - GOV.UK
www.mhra.gov.ukPL 31388/0003-4 UKPAR Alpex Pharma (UK) Ltd, Meloxicam 7.5mg and 15mg Orodispersible Tablets 3 Scientific Discussion INTRODUCTION Based on the review of the data on quality, safety and efficacy, the UK granted
The Human Medicines Regulations 2012 – …
www.mhra.gov.ukThe Human Medicines Regulations 2012 – description of each Part This document provides a brief overview of each Part of the Human Medicines Regulations 2012 …
Human, Regulations, Descriptions, Medicine, 2012, Human medicines regulations 2012, Human medicines regulations 2012 description of
PL 00010/0643 - GOV.UK
www.mhra.gov.ukUKPAR Canesten HC Cream PL 00010/0643 6 All excipients comply with their respective European Pharmacopoeia monographs, except triceteareth-4-
FULTIUM -D 800 IU CAPSULES - GOV.UK
www.mhra.gov.ukVitamin D deficiency, with levels of 25(OH)D below 25nmol/L (10ng/ml), could result in the disease rickets (or osteomalacia). The disease resulting as a deficiency is considered to be due to malabsorption
Deficiency, Capsule, Vitamin, Fultium d 800 iu capsules, Fultium, Vitamin d deficiency
GLYCOPYRRONIUM BROMIDE 0.2MG/ML …
www.mhra.gov.ukUKPAR Glycopyrronium Bromide 0.2 mg/ml Solution for Injection PL 00156/0115 1 GLYCOPYRRONIUM BROMIDE 0.2MG/ML SOLUTION FOR INJECTION (PL 00156/0115)
Solutions, Injection, 0115, Solution for injection pl 00156, 00156, Solution for injection, Pl 00156
Public Assessment Report UKPAR Canesten Combi …
www.mhra.gov.ukThis is a summary of the Public Assessment Report (PAR) for Canesten Combi Pessary & External Cream 500mg / 2% w/w pessary & cream (PL 00010/0653).
DCPAR for Ampicillin-Salbactam 1 g--0 5 and 2 g-1 g ...
www.mhra.gov.ukPAR Ampicillin/Sulbactam 1 g/0.5 g and 2 g/1 g powder for Solution for Injection or Infusion UK/H/4322/001-2/DC 1 Public Assessment Report Decentralised Procedure
Public Assessment Report Mutual Recognition …
www.mhra.gov.ukPAR Sayana 104mg/0.65ml Suspension for Injection UK/H/0960/001/MR 1 Public Assessment Report Mutual Recognition Procedure SAYANA 104MG/0.65ML SUSPENSION FOR INJECTION
Assessment, Report, Public, Procedures, Mutual, Recognition, Public assessment report mutual recognition, Public assessment report mutual recognition procedure
Public Assessment Report Decentralised Procedure …
www.mhra.gov.ukPublic Assessment Report Decentralised Procedure LIOTHYRONINE SODIUM 20 MICROGRAM TABLETS (liothyronine sodium) Procedure No: UK/H/6516/001/DC
Assessment, Report, Public, Procedures, Public assessment report decentralised procedure, Decentralised
Related documents
European Medicines Agency guidance for …
www.ema.europa.euEuropean Medicines Agency Guidance for Applicants seeking scientific advice and protocol assistance EMA/4260/2001 Page 3/23 . Instructions for users
European, Scientific, Agency, Medicine, European medicines agency
European Medicines Agency
www.ema.europa.euEuropean Medicines Agency 7 Westferry Circus, Canary Wharf, London, E14 4HB, UK Tel. (44-20) 74 18 85 75 Fax (44-20) 75 23 70 40 E-mail: mail@emea.europa.eu http://www.emea.europa.eu
1. Name of pharmacopoeia - WHO
www.who.int12 | 8. Collaboration with and/or being part of a (different) national/regional pharmacopoeia (3/4) Observership to the Ph. Eur.: – Allows for participation in the scientific work of the European Pharmacopoeia
UNICEF/UNDP/World Bank/WHO Special …
www.who.intUNICEF/UNDP/World Bank/WHO Special Programme for Research and Training in Tropical Diseases (TDR) HANDBOOK NON-CLINICAL SAFETY TESTING
Research, Special, Programme, Who special, Who special programme for research and